AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$HUM

Humana’s (NYSE:HUM) Q3 2026 sales top estimates but full-year sales guidance misses expectations

Humana reported Q3 2026 revenue of $41.16 billion, exceeding estimates by 0.7%, and adjusted EPS of -$0.70, beating estimates by 30.3%. Management raised full-year adjusted EPS guidance to $9.50. Operating margin decreased to 0.2%, while free cash flow margin improved to 4.9%. Customer count rose to 18.04 million.

Original reporting
finance.yahoo.com
Published Nov 6, 2026, 11:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Humana’s (NYSE:HUM) Q3 2026 sales top estimates but full-year sales guidance misses expectations — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$HUMBullishHigh
01

Why it matters

The mixed results—quarterly beat versus guidance miss—create uncertainty, likely prompting short-term price volatility.

02

Market read

Earnings beat with guidance miss is a primary catalyst for Humana's stock movement, relevant for traders today.

03

What to watch

Potential impact of upcoming policy changes or cost management initiatives not reflected in guidance.

Relevance 9/10Novelty 9/10Timing: post-market today

Background

Humana's Q3 2026 earnings release includes revenue of $41.16B and adjusted EPS of -$0.70, both beating estimates, but full-year EPS guidance was raised only to $9.50, missing consensus.

Company-level read

Ticker impact

$HUMBullishHigh confidence
Context

Humana reported Q3 2026 revenue and EPS beats but issued full-year EPS guidance below expectations.

Expected impact

likely downside as market prices in weaker full-year outlook

Evidence & confidence

Investors often react negatively to guidance that falls short of consensus, especially after a beat on the quarter.

Market effects

Sector

Health insurance sector may see broader scrutiny as guidance shortfalls raise concerns about cost pressures.

Regional

U.S. healthcare stocks could face modest pullback.

Global

Limited to U.S. markets; minimal global ripple.

Counterpoint

What could challenge this read

Some analysts may view the EPS beat as a sign of operational strength despite guidance miss.

Key entities

  • Company
    Humana Inc.

    U.S.-listed health insurance provider.

Read at source← All news

StoryHumana posts Q3 2026 results and lifts FY2026 adjusted EPS guidance to at least $9.50

Also covered by

6 outlets

Related articles

$HUMHighAI 8/10

Humana Raises Profit Floor on Lower Costs

Humana (HUM) raised its 2026 adjusted earnings guidance to at least $9.50 per share from $9.00, citing lower costs. Q3 insurance benefit ratio was 93.7%, better than expected. Shares fell 0.59% in pre-market trading. Humana's Medicare Advantage membership grew 23% this year.

asktraders.com
$HUMHighAI 8/10

HUM Q3 FY2026 earnings call

Humana Inc. reported Q3 2026 earnings exceeding expectations, raising full-year adjusted EPS guidance to at least $9.50. The company cited favorable medical cost trends and strong execution. Management highlighted progress in clinical quality, Medicaid expansion, and capital allocation, including a divestiture and a new joint venture. Humana expects 2027 Medicare Advantage membership growth and an 8%-9% medical cost trend, with risks and opportunities outlined.

finance.biggo.com
$HUMHighAI 8/10

[Humana Q3 2026 Earnings Call] Humana Lifts Full-Year EPS Guidance to at Least $9.50 as Medical Cost Trend Lands at Low End of 7%-8% Range

Humana Inc. raised its full-year 2026 adjusted EPS guidance to at least $9.50 per share from $9.00, citing favorable medical cost trends. The company reported strong STARS performance and plans to use excess funds for investments and shareholder returns. Humana also announced balance sheet improvements through divestitures and a new joint venture with BlackRock. Management expects 2027 Medicare Advantage membership growth and higher medical cost trends.

finance.biggo.com
$HUMMed

Humana Lifted Its Profit Forecast As Medical Costs Cooled

Humana raised its profit forecast due to lower medical costs, despite posting an adjusted quarterly loss. The company reported a 93.7% medical cost ratio, which may influence its Medicare Advantage pricing. Humana's individual Medicare Advantage membership grew 23% year-to-date, with a target of 25% growth by 2026 and a pretax margin of at least 3% by 2028.

finimize.com